Faced with continuing failure in Alzheimer’s drug development, researchers are grappling with the best route forward. And as efforts to modify disease progression or even better symptomatic treatment disappoint, despite the best efforts of giants in the biopharma industry, there is growing recognition of the need to move even earlier in Alzheimer’s disease – toward prevention.
Heading off the degenerative disease, maybe even 10 or 20 years before symptoms develop, is an intriguing idea, though some formidable challenges stand in the way. Better disease understanding and better diagnostic tools may help. Alzheimer's disease is defined by the build-up of proteins – amyloid beta into plaque and tau into tangles – associated with cognitive decline
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?